# A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis

> **NCT02671188** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** GSK3050002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02671188
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06-01
- **Primary completion:** 2019-08-09
- **Final completion:** 2019-08-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was stopped before any subjects were treated, consequently there are no results for the study.
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02671188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02671188, "A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT02671188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*